Yahoo Finance

Press Release

Nicox: 2022 Extraordinary Shareholder Meeting

July 8, 2022 – release at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, Informs its shareholders that the Extraordinary general meeting convened on first call on Monday July 11, 2022, cannot be held as the quorum required by law will not be reached.

The shareholders of Nicox are thus convened on second call for an Extraordinary general meeting on the same resolutions and the same agenda on Thursday July 28, 2022 at 2:00 pm CET in the offices of BuroClub - Drakkar 2 - Bâtiment D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis - France.



The documents mentioned in articles R.22.10-23 of the French Code de commerce, including a proxy voting form, are sent to the shareholders upon written request. These documents are also made available to shareholders at the headquarters of the Company and on its website (www.nicox.com).



Shareholders may vote by proxy, by internet or by attending the Extraordinary shareholder meeting in person. A guide explaining how to vote, and notably how to vote by internet, is posted on Nicox’s website. Shareholders may also contact the Company’s Investor Relations team at ag2022nicox@nicox.com for any question on the voting process. The proxy forms sent by correspondence or the electronic votes for the Extraordinary general meetings of July 11, 2022 remain valid for the Extraordinary general meeting of July 28, 2022.

About Nicox

Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for dry eye disease. Nicox generates revenue from VYZULTA^® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE^® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment C: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage

Bryan, Garnier & Co         Dylan van Haaften        Paris, France
Edison Investment Research        Pooya Hemami        London, UK
H.C. Wainwright & Co        Yi Chen        New York, U.S.
Kepler Cheuvreux        Arsene Guekam        Paris, France

The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.